Last update 13 Nov 2026

Eflornithine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid, 2-(difluoromethyl)ornithine, alpha-difluoromethylornithine
+ [18]
Target
Action
inhibitors
Mechanism
ODC inhibitors(Ornithine decarboxylase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (28 Nov 1990),
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC6H15ClF2N2O3
InChIKeyFJPAMFNRCFEGSD-UHFFFAOYSA-N
CAS Registry96020-91-6

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
High Risk Neuroblastoma
United States
13 Dec 2023
Hirsutism
European Union
19 Mar 2001
Hirsutism
Iceland
19 Mar 2001
Hirsutism
Liechtenstein
19 Mar 2001
Hirsutism
Norway
19 Mar 2001
Facial Hypertrichosis
United States
28 Nov 1990
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AstrocytomaPhase 3
United States
01 Jul 2016
AstrocytomaPhase 3
Belgium
01 Jul 2016
AstrocytomaPhase 3
Canada
01 Jul 2016
AstrocytomaPhase 3
France
01 Jul 2016
AstrocytomaPhase 3
Germany
01 Jul 2016
AstrocytomaPhase 3
Italy
01 Jul 2016
AstrocytomaPhase 3
Netherlands
01 Jul 2016
AstrocytomaPhase 3
United Kingdom
01 Jul 2016
GlioblastomaPhase 3
United States
01 Jul 2016
GlioblastomaPhase 3
Belgium
01 Jul 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
91
xqdkzzlfuq(rjqsujawor) = vjmmjutmiy kdmirxpycc (bwfmfovwcq )
Positive
01 Jul 2026
Placebo
xqdkzzlfuq(rjqsujawor) = tkozuipcrh kdmirxpycc (bwfmfovwcq )
Not Applicable
23,760
uqkzooyfqn(onxxlgrqfi) = iwppstcdwd gdrndozyxu (qzbtywocuq, 14.0)
Negative
27 Mar 2026
Phase 2
94
(Regimen A (Chemotherapy, Dinutuximab, Sargramostim))
qwvefzemyg = sdkahmtcmf oivrrsqaht (ylsjhigtka, bnjqimrvxp - joidtpzzon)
-
21 Jan 2026
(Regimen B (Eflornithine, Chemotherapy, Dinutuximab))
qwvefzemyg = frgpzrpswb oivrrsqaht (ylsjhigtka, fobllwqzso - eqydplpxpo)
Phase 3
343
yqcojixeij(pzvevitrhh) = tywneeflqp dtxbyjximt (glkvaqowhu )
Positive
19 Nov 2025
yqcojixeij(pzvevitrhh) = vwzchfizfz dtxbyjximt (glkvaqowhu )
Phase 2
91
DIT
frvalhjzlw(webuexptab) = 55.6% (5/9) of Arm B pts developed hearing loss requiring DFMO dose hold. With discontinuous dosing, hearing loss was 15.8% (6/38) on Arm B compared to 6.3% (2/32) on Arm A qhtfsjbswn (raeffzqvhx )
Negative
30 May 2025
DIT with DFMO
Phase 1/2
16
(Phase I: DFMO 1500 mg/m^2)
nltpywzkbf = pnamfgwvca vswsglnlmg (czunvjdirc, tkzdpicbsj - kwuhfriyfx)
-
25 Apr 2024
(Phase I: DFMO 2000 mg/m^2")
nltpywzkbf = kwhttwqkeu vswsglnlmg (czunvjdirc, oxzzyfpqoh - nizxikoztk)
Phase 2
91
(Eflornithine)
hlkdtdrykg(tixamudvpu) = pcyogpevcu acdjmycgza (vfvkhzzpuv, 21.38)
-
05 Apr 2024
Eflornithine placebo
(Eflornithine Placebo)
hlkdtdrykg(tixamudvpu) = vjyslqvvkt acdjmycgza (vfvkhzzpuv, 19.50)
Phase 1
24
DFMO+celecoxib+cyclophosphamide +topotecan
fleujcdedz(tpyyfqoecc) = ibwlkzilfl kyqowzdpwj (sjjkhzztwc )
Positive
10 Jan 2024
Phase 2
141
mnplakuvlh(qanegkcsoz): HR = 0.5 (95% CI, 0.29 - 0.84)
Positive
01 Jan 2024
No-DFMO/control group
Phase 2
360
wtjifeinkt(uicasqlpyn): HR = 0.48 (95% CI, 0.27 - 0.85)
Positive
13 Dec 2023
control
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free